1. Introduction {#sec1}
===============

Cisplatin is a commonly used chemotherapy agent in the treatment of a number of malignant tumors, both in children and adults. This type of chemotherapy is often associated with a dose-dependent bilateral high frequency sensorineural hearing loss. The incidence of cisplatin-induced hearing loss is reported to range from 22 to 77% ([@bib40], [@bib2], [@bib6], [@bib5], [@bib19], [@bib21]). The range reflects differences in cisplatin dose, as well as in measures of hearing outcomes. Additional risk factors for cisplatin-induced ototoxicity include children under five years in age, prior irradiation to the head and neck greater than 40 Gy, and prior hearing loss ([@bib28], [@bib24], [@bib17]). Vestibular function can also be damaged by platinum-based toxicity ([@bib29]). The exact cellular mechanisms by which cisplatin causes cochlear hair cell loss is unclear. There is believed to be some degree of resultant oxidative stress with subsequent activation of apoptotic pathway in outer hair cells and the stria vascularis ([@bib37]). Other possible mechanisms include the activation of voltage-dependent big conductance potassium channels in type 1 spiral ligament fibrocytes of the lateral wall of the cochlea leading to disruption of the electrochemical gradient and the activation of apoptotic pathways ([@bib25]). Finally, other postulated mechanisms include disruption to nuclear excision repair leading to aggregates of cisplatin-induced DNA adducts and inflammation from the induction of pro-inflammatory cytokines in the cochlea ([@bib11], [@bib41]).

Sodium thiosulfate (STS) has shown potential as an otoprotective agent against platinum-based chemotherapy ([@bib23], [@bib30], [@bib18], [@bib8], [@bib31], [@bib50]). STS is currently approved by the United States Food and Drug Administration (USFDA) as an antidote for cyanide and nitroprusside toxicity, and it is also used as an off-label treatment for cisplatin-related nephrotoxicity and calciphylaxis ([@bib13], [@bib3], [@bib32], [@bib49], [@bib10]). Unlike several other potential otoprotectants, STS has been shown to act as both an antioxidant as well as a chelating agent ([@bib10], [@bib48], [@bib27]). The chelating properties of the sulfur-thiol functional group are believed to be responsible for the otoprotective effects of STS by binding to and inactivating the platinum ([@bib7]). The thiol compound may also act to scavenge reactive oxygen species produced by the platinum, thus preventing the initiation of the apoptotic pathway ([@bib7]).

STS administered intravenously has been shown to prevent cisplatin-induced ototoxicity in animal models and *in vivo* ([@bib23], [@bib30], [@bib18], [@bib8], [@bib31], [@bib50]). However, a major concern to this mode of delivery is that it may potentially reduce the tumoricidal activity of the platinum. Sodium thiosulfate is believed to bind to cisplatin, forming a complex that is then excreted by the kidneys. Such chelation could negatively impact the desired activity of the platinum. There are conflicting reports of reduced tumoricidal properties of STS in vitro ([@bib14], [@bib47]). A recent *in vivo* study by Freyer et al. showed that infusion of intravenous 6% STS solution after cisplatin therapy was not found to have a statistically significant otoprotective effect in children with pediatric cancer. Additionally, patients with disseminated disease treated with STS were shown to have significantly lower 3-year overall survival (45%) compared to the control group (84%) ([@bib9]).

Local application of STS to the round window may represent an alternative mode of delivery that may allow for higher intracochlear concentrations while minimizing interference with the tumoricidal effects of cisplatin. There have been a few recent studies showing intratympanic STS as an effective means to prevent cisplatin-induced ototoxicity in animals ([@bib44], [@bib1]). However, the pharmacokinetics of STS via round window diffusion are not yet well understood. The purpose of this study is to establish pharmacokinetic parameters of STS in perilymph after intratympanic administration.

2. Materials and methods {#sec2}
========================

2.1. Animal preparation and procedures {#sec2.1}
--------------------------------------

Ten retired breeder Hartley albino Guinea pigs of both sexes (Charles River, Kiβlegg, Germany) were used. Twenty ears were randomly separated into 2 groups based on STS (Hope Pharmaceuticals, Scottsdale, AZ) concentration: 50 mg/mL (5% solution) or 250 mg/mL (25% solution) ([Fig. 1](#fig1){ref-type="fig"}). These concentrations of STS were selected based on previous studies determining their safety. A 25% solution of STS has been used ototopically to prevent myringosclerosis in rat models and a 6% solution has also been used safely when administered ototopically in mice models ([@bib33], [@bib42]). Each Guinea pig was placed under general anesthesia using inhaled 1--5% isoflurane for induction, then intubated endotracheally and placed on 2--4% isoflurane for maintenance anesthesia. The body temperature was maintained throughout the procedure with a temperature-controlled heating blanket. The head and neck was then shaved and 1% lidocaine with 1:100,000 epinephrine was injected in the postauricular soft tissue. A postauricular incision was then made extending to the neck and soft tissue was elevated off of bone. With the aid of an operating microscope, a cutting bur was then used on a high-speed drill to enter the bulla. The vertical portion of the facial nerve was drilled away in order to obtain adequate visualization of the round window. This procedure was then repeated on the contralateral ear.Fig. 1Flowchart of STS Randomization and perilymph sampling.Fig. 1

The protocol for STS middle ear application and perilymph sampling was adapted from similar studies looking at the pharmacokinetics of intratympanic steroids ([@bib4], [@bib36], [@bib34], [@bib45], [@bib12], [@bib26]). With the head in a neutral position, STS was placed in the middle ear space for 30 min. An operating microscope was used to confirm the round window was covered with STS. After 30 min, we confirmed that the round window was still covered with STS ensuring none was lost via the Eustachian tube. The bulla was then suctioned and irrigated with normal saline. A 26-gauge needle attached to a 10 μL Hamilton syringe was then inserted into the round window, and 2 μL of perilymph was then aspirated from the scala tympani. Perilymph samples were obtained serially at 0, 30, 60, 180, and 360 min after the bulla was cleaned. In order to prevent perilymph lost between samples, the Guinea pig heads were kept in a neutral position for all samples. Additionally, no gush of perilymph was noted upon perforation of the round window. Samples were stored at −20° C and later analyzed by high pressure liquid chromatography (HPLC). Once all samples were obtained, intraperitoneal pentobarbital was injected for euthanasia. This study was performed in accordance with the Public Health Service Policy on Humane Care and Use of Laboratory Animals, the NIH Guide for the Care and Use of Laboratory Animals, and the Animal Welfare Act. The Institutional Animal Care and Use Committee of SUNY Upstate Medical University approved the animal use protocol.

2.2. High pressure liquid chromatography (HPLC) {#sec2.2}
-----------------------------------------------

STS concentrations were quantitatively analyzed by HPLC using an LC-20AT with a SPD-M20A UV--Vis detector (Shimadzu, Kyoto, Japan) and a LiChrospher RP-select B LiChroCART 250-4 anion exchange column (EMD Millipore Corp, Darmstadt, Germany). All samples were prepared using a method similar to that described by [@bib43]. Two μL samples were diluted in 8 μL of sterile water. Ten μL of 5 mM monobromobimane in acetonitrile was then added and the mixture was allowed to sit for 60 min in the dark at room temperature. Ten μL of 0.05 M KCl-HCl buffer was then added. Ten μL of this mixture was then submitted to the HPLC system using a mobile phase of 40% acetonitrile and 60% 36 mM succinate (pH 5.0) with a flow rate of 1.0 mL/min. Drug concentrations were calculated based on peak height. A linear standard curve was calibrated by testing serial dilutions of STS. Samples with an STS concentration less than 0.9 mg/mL were unable to be detected.

2.3. Data analysis {#sec2.3}
------------------

Statistical analysis was performed using SPSS Version 22 (IBM Corporation, Armonk NY, USA). Pharmacokinetic parameters and perilymph concentration--time curves were generated for each concentration of STS. The results are presented as means ± standard deviation (SD) whenever possible. Half-life and AUC were determined by generating a logarithmic line of best fit using the SPSS software.

3. Results {#sec3}
==========

The pharmacokinetic parameters of each concentration of STS are summarized in [Table 1](#tbl1){ref-type="table"}. Peak concentrations of STS for the 250 mg/mL dose was found to be 7.27 mg/mL with a standard deviation of 0.83. The half life of STS 250 mg/mL within perilymph was 0.74 h (44.4 min). The half-life of STS 50 mg/mL was unable to be determined due to the inability to detect concentrations less than 0.9 mg/mL. Perilymph concentration--time curves are shown in [Fig. 2](#fig2){ref-type="fig"}.Table 1Pharmacokinetic profile of STS in perilymph.Table 1ParametersSTS 250 mg/mLSTS 50 mg/mLC~max~ (mg/mL)[a](#tbl1fna){ref-type="table-fn"}7.27 ± 0.831.63 ± 0.17T~max~ (hr)00AUC (mg hr/mL)13.461.21T~1/2~ (hr)0.74--[^1]Fig. 2Perilymph Concentration--Time Curves After Intratympanic STS. \*Brackets note the standard deviation of each time point.Fig. 2

4. Discussion {#sec4}
=============

In light of the potential for systemic STS to reduce the tumoricidal effects of cisplatin, researchers have sought an alternate mode of delivery. Recent animal studies have examined the effect of sodium thiosulfate delivered locally to the middle ear space. Stocks et al., in 2004 demonstrated an otoprotective effect of 6% STS delivered to the middle ear space of Guinea pigs via both daily injections and continuous infusions ([@bib42]). [@bib44] showed complete prevention of the ototoxic effects of cisplatin in Guinea pigs treated with round window application of 10 mM (1.58 mg/mL) solution of STS via auditory brainstem response (ABR) studies. They also showed that both the compound action potential (CAP) and distortion product otoacoustic emissions (DPOAE) were preserved, and both outer hair cells (OHC) and inner hair cells (IHC) were preserved ([@bib44]). [@bib1] noted the prevention of IHC and OHC loss when a 0.1 M (15.8 mg/mL) concentration of STS was administered via a hyaluronic acid gel applied to the round window prior to cisplatin administration ([@bib1]). A study by [@bib46] showed higher DPOAEs in Guinea pigs treated with intratympanic 15 mg/mL STS compared to a control, but this was not found to be statistically significant ([@bib46]).

This is the first study showing the perilymph pharmacokinetics of STS after intratympanic administration. Perilymph concentrations of STS following intratympanic administration in this study were about 200--1000 fold higher compared to perilymph concentrations following intravenous administration of a103 mg/kg STS solution found by [@bib35]. This shows that intratympanic administration of STS may be a more effective method of delivering STS to the perilymph than intravenously. STS has been shown to be safely used ototopically in the prevention of myringosclerosis in rats at a concentration of 250 mg/mL ([@bib33]). Stocks et al., in 2004 found STS to be safe with application to the middle ear space of Guinea pigs at a concentration of 6% ([@bib42]). A 5% STS solution has also been used to relieve iodine-induced mucosal irritation of the esophagus in the gastroenterology literature ([@bib20]). Our study used 5% and 25% STS solutions, and no evidence of a local inflammatory reaction or gross toxicity were noted throughout the study at either concentration. However, exposure times in this study were limited to 30 min, therefore the potential for more prolonged or repeated applications of STS to generate adverse local reactions remains unclear.

When considering this as a potential treatment modality, intratympanic STS should be administered around the time of peak cisplatin concentrations in perilymph. Multiple studies have looked at the pharmacokinetics of cisplatin in perilymph showing maximum concentrations occurring between 10 and 30 min after intravenous administration ([@bib15], [@bib16], [@bib22], [@bib38]). Based on these pharmacokinetic parameters, STS should be administered intratympanically immediately prior to administering IV cisplatin. This could be done either via an intratympanic injection or ototopical drops after myringotomy tube placement. Intratympanic injections would likely result in higher perilymph concentrations, however ototopical drops after myringotomy tube placement may be better tolerated and logistically easier to administer both at the time of cisplatin administration and in the ensuing days. With either route of application, losses from the Eustachian tube or through the myringotomy render some variability in the drug delivery to the perilymph.

There were some limitations encountered during this study. Samples were taken only from the base of the cochlea, so it cannot be reliably stated that STS was distributed evenly to the remaining portions of the cochlea or the vestibular system. Also, the use of a UV--Vis detector for HPLC is at least 100-fold less sensitive than a fluorescent detector. A fluorescent detector would have allowed us to detect smaller concentrations of STS and provided a more complete pharmacokinetic profile of STS 50 mg/mL, as well as assess serum samples for systemic absorption. Perilymph samples were also double that of similar pharmacokinetic studies (2 μL instead of 1 μL) to improve the likelihood of detection of STS, but this also increases the dilution of samples with CSF as described by [@bib39]. This effect will be more pronounced with successive sampling in the same animal, thus making our initial samples the most reliable. As a result, perilymph concentrations after the initial sampling may be underestimated and the calculated half-life of STS within the perilymph may actually be longer. Despite the dilution of subsequent samples, it is important to note that we were still able to identify STS within our samples up to 6 h after the initial sample.

5. Conclusion {#sec5}
=============

This study shows that intratympanic STS has the potential to be a localized therapy in the prevention of cisplatin-induced ototoxicity. Local application of STS will allow for higher perilymphatic concentrations while limiting any interference with the tumoricidal effects of cisplatin.
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[^1]: Range determined by standard deviation.
